Neuren completes enrolment in Phelan-McDermid Phase 2 trial
Filed with ASX · · 2 pages · English
Melbourne, Australia:Neuren Pharmaceuticals (ASX: NEU) today announced that enrolment of subjects into its Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome has now been completed. Top- line results from the trial are expected to be available in December 2023. Neuren CEO Jon Pilcher commented “We are grateful to all the people at the trial sites in the United States and in the Phelan-
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Neuren opens first site in US for Prader-Willi Phase 2 trial
- Neuren receives US$40m milestone payment
- Q1 2023 quarterly activity and cash flow report
- DAYBUE (trofinetide) launched in US - Neuren earns US$40m
- FDA approves Daybue - the first treatment for Rett syndrome
Later from Neuren Pharmaceuticals
- Neuren and Acadia expand global partnership for trofinetide
- Neuren receives US$100m for expanded DAYBUE agreement
- Q2 2023 quarterly activity and cash flow report
- S&P DJI Announces September 2023 Quarterly Rebalance
- Q3 2023 quarterly activity and cash flow report
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals